Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2026
Effectiveness and Safety of a High G' Hyaluronic Acid Injectable for Jawline Definition: A Randomized Controlled Clinical Investigation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shridharani Sachin M, Ablon Glynis, Hevia Oscar, Weiss Robert, Joseph John, Montes Jose R, Coleman Kyle, Donath Alexander, George Rosalyn, Biesman Brian, Rohrich Rod, Cohen Joel L, Somenek Michael, Baumann Leslie, Cox Sue E, Nilsson Anna, Rugheimer Annika, Weinberg Felipe, Bromée Torun
Аннотация
BACKGROUND: HASHA is a novel, NASHA HD Technology, hyaluronic acid (HA) injectable, optimized for lower-face shaping.
OBJECTIVES: This multicenter study evaluated effectiveness and safety of HASHA in improving jawline definition for up to 2 years.
METHODS: Subjects with moderate-to-very-severe volume deficiency on the Galderma Jawline Scale (GJS) were randomized 3:1 to HASHA injections (via needle or cannula) or no-treatment control. At Month 12, HASHA-treated subjects were offered optional re-treatment and controls were offered first treatment with HASHA.
RESULTS: At Month 3, the HASHA group (N = 168) had a statistically significant (p < .001) higher ≥1-grade blinded evaluator-assessed GJS responder rate than the no-treatment group (N = 68) (85.1% vs 14.3%, primary endpoint), which remained high in the HASHA group at Months 12 (67.1%) and 24 (69.0% without re-treatment; 81.3% with Month-12 re-treatment). Treating-investigator-assessed Global Aesthetic Improvement Scale improvement rates were ≥84% at Months 3 to 24. Most HASHA-treated subjects reported improved overall satisfaction with their appearance (≥70%) and natural-looking results (≥82%) through Month 24. Treatment-related adverse events, all mild or moderate, occurred in 14.5% of subjects after initial treatment.
CONCLUSION: HASHA was superior to no-treatment for improving jawline definition, with improvement lasting throughout 24 months. Subject satisfaction was high. Treatment was well tolerated.
OBJECTIVES: This multicenter study evaluated effectiveness and safety of HASHA in improving jawline definition for up to 2 years.
METHODS: Subjects with moderate-to-very-severe volume deficiency on the Galderma Jawline Scale (GJS) were randomized 3:1 to HASHA injections (via needle or cannula) or no-treatment control. At Month 12, HASHA-treated subjects were offered optional re-treatment and controls were offered first treatment with HASHA.
RESULTS: At Month 3, the HASHA group (N = 168) had a statistically significant (p < .001) higher ≥1-grade blinded evaluator-assessed GJS responder rate than the no-treatment group (N = 68) (85.1% vs 14.3%, primary endpoint), which remained high in the HASHA group at Months 12 (67.1%) and 24 (69.0% without re-treatment; 81.3% with Month-12 re-treatment). Treating-investigator-assessed Global Aesthetic Improvement Scale improvement rates were ≥84% at Months 3 to 24. Most HASHA-treated subjects reported improved overall satisfaction with their appearance (≥70%) and natural-looking results (≥82%) through Month 24. Treatment-related adverse events, all mild or moderate, occurred in 14.5% of subjects after initial treatment.
CONCLUSION: HASHA was superior to no-treatment for improving jawline definition, with improvement lasting throughout 24 months. Subject satisfaction was high. Treatment was well tolerated.